Lowering Barriers to R&D Innovation
We are a global, not-for-profit alliance of life science companies, vendors, publishers, and academic groups that work together to lower barriers to innovation in R&D.
Our projects transform R&D innovation through pre-competitive collaboration. We bring together the key constituents to identify the root causes that lead to R&D inefficiencies. We develop best practices and technology pilots to overcome common obstacles.
Our members collaborate as equals on open projects that generate significant value for the worldwide life sciences community.
With the launch of our Interactive Project Portfolio Platform (IP3) we are embracing a new level of openness, access, and transparency around our idea-to-project process. The platform is open to the public to submit new ideas, comment and vote on proposed ideas, and monitor the progress of our projects.
April and the BioITWorld Expo in Boston saw the second running of the Pistoia Alliance Conference, and we once again overfilled the facility at Thomson Reuters, who generously offered to host our meeting for a second year.
Last week I was part of a very interesting email exchange on the topic of biomarker exchange standards. The correspondents were Sandor Szalma of Johnson & Johnson, who is heading up the embryonic working group on this subject, and James McGurk, director of informatics at Daiichi Sankyo Pharma Development.